2026-09-24T14:14:08-05:00 2025-12-31 251622758 MAHER DUESSEL CPA'S 503 MARTINDALE STREET SUITE 600 PITTSBURGH PA 15212 990 2025-01-01 460902111 RTOG FOUNDATION INC RTOG 4123395336 NOVA TOWER 2 2 ALLEGHENY CTR 1200 PITTSBURGH PA 15212 QUYNH-THU LE CHAIRMAN 4123395336 2026-09-24 1 AMY LEWIS P01360302 4124715500 2025 X QUYNH-THU LE NOVA TOWER 2 2 ALLEGHENY CTR 1200 PITTSBURGH PA 15212 16496829 0 X WWW.RTOG.ORG X 2012 PA TO ORGANIZE & PROVIDE FUNDING FOR MULTI-CENTER CLINICAL RESEARCH ACTIVITIES IN ONCOLOGY. 14 14 0 14 0 0 4176134 3847538 9362425 10596770 420007 395850 41495 5000 14000061 14845158 0 0 0 0 0 0 0 0 0 12705224 13471121 12705224 13471121 1294837 1374037 20327245 22281077 10250384 10464726 10076861 11816351 X THE MISSION OF RTOG FOUNDATION, INC. (RTOGF) IS TO:(1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS, (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH, (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION, (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOGF'S MEMBERSHIP IN NRG ONCOLOGY, (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOGF'S RESEARCH MISSION, (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOGF IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES, AND (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOGF RESEARCH ENTERPRISE. 0 0 12731598 10601770 RTOGF'S PRIMARY PROGRAM CONSTITUTES THE FOLLOWING: (1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS, (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH, (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION, (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOGF'S MEMBERSHIP IN NRG ONCOLOGY, (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOGF'S RESEARCH MISSION, (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOGF IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES, AND (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOGF RESEARCH ENTERPRISE. 12731598 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 PA X JULIE KARDELL 4123395336 NOVA TOWER 2 2 ALLEGHENY CTR 1200 PITTSBURGH PA 15212 X DOW WILSON DIRECTOR 1.00 X 0 0 0 GRAHAM BURNETTE ESQ DIRECTOR 1.00 X 0 0 0 JEFF MICHALSKI MD MBA TREASURER 1.00 X X 0 0 0 JIM DIGNAM PHD DIRECTOR 1.00 X 0 0 0 KRISTIN HIGGINS MD DIRECTOR 1.00 X 0 0 0 LISA KACHNIC MD DIRECTOR 1.00 X 0 0 0 MITCHELL MACHTAY MD PRESIDENT & CEO 5.00 X X 0 0 0 QUYNH-THU LE MD CHAIR 5.00 X X 0 0 0 SETH ROSENTHAL MD DIRECTOR 1.00 X 0 0 0 STUART WONG MD SECRETARY 1.00 X X 0 0 0 SUE YOM MD DIRECTOR 1.00 X 0 0 0 WALTER J CURRAN JR MD DIRECTOR 1.00 X 0 0 0 MARK MISHRA MD DIRECTOR 1.00 X 0 0 0 EDWIN POSADAS MD DIRECTOR 1.00 X 0 0 0 0 0 0 0 0 0 0 RXCROSSROADS BY MCKESSON P O BOX 846025 DALLAS TX 75284 DRUG DISTRIBUTION 422469 UNIVERSITY OF CALIFORNIA -UCSF 2340 SUTTER ST ROOM S341 SAN FRANCISCO CA 94115 BIOSPECIMEN BANKING 384194 NSABP FOUNDATION INC 2 1200 ALLEGHENY SQUARE E PITTSBURGH PA 15212 ACCOUNTING AND CONSULTING 373373 PRINCESS MARGARET CANCER CENTRE 610 UNIVERSITY AVE TORONTO ONTARIO CA M5G 2M9 RESEARCH STUDIES 246696 CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES CA 90048 RESEARCH STUDIES 188550 9 3826038 21500 3847538 INDUSTRY REVENUE 541700 10596770 10596770 10596770 401639 401639 1645882 1651671 -5789 -5789 -5789 MISCELLANEOUS 900099 5000 5000 5000 14845158 10601770 0 395850 X 9885 9885 366283 2800 363483 2246602 2185602 61000 2488 2488 8206 8206 SUB-AWARD RESEARCH PROJ 8126667 7864987 261680 SITE EXPENSES 2676419 2676419 MISCELLANEOUS 33876 1188 32688 POSTAGE & SHIPPING 695 602 93 13471121 12731598 739523 0 8232069 4140951 3702103 6489326 5097505 5414792 15281 2390687 5374671 889600 861337 20327245 22281077 2342111 3420641 7908273 7044085 10250384 10464726 X 10076861 11816351 10076861 11816351 20327245 22281077 1374037 365453 0 X X 0 1 X 1 1 1 X 5887228 4276831 4287692 4176134 3847538 22475423 5887228 4276831 4287692 4176134 3847538 22475423 22475423 1 5 181070 420007 401639 1002722 27000 41495 5000 73495 23551640 36045503 0.95430 0.96950 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - SDMC INCOME - 2023 AMOUNT: $ 27,000. 2024 AMOUNT: $ 41,495. 2025 AMOUNT: $ 5,000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 15210611 365453 365453 14845158 0 14845158 13471121 0 13471121 0 13471121 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE RETURN WILL THEN BE REVIEWED BY THE SECRETARY-TREASURER AND APPROVED. THE RETURN WILL THEN BE MADE AVAILABLE FOR ALL DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, STAFF, VOLUNTEERS, CLINICAL INVESTIGATORS, AND ALL OTHERS REPRESENTING OR ACTING ON BEHALF OT RTOGF. IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST. THE DISCLOSURE IS REVIEWED BY THE RTOGF ADMINISTRATOR WITH GUIDANCE FROM RTOGF LEGAL COUNSEL. ANY IDENTIFIED FINANCIAL CONFLICT OF INTEREST (FCOI) WILL BE REVIEWED WITH THE AFFECTED INVESTIGATOR AND, IF APPLICABLE, REPORTED TO NIH WITHIN 60 DAYS OF DISCOVERY AND ACTIONS TO MANAGE, REDUCE, OR ELIMINATE THE FCOI WILL BE TAKEN BY THE ADMINISTRATOR OF THE RESEARCH ACTIVITY INVOLVED AND INCLUDED IN THE REPORT TO NATIONAL INSTITUTES OF HEALTH (NIH). MANAGEMENT OF AN IDENTIFIED FCOI WILL INCLUDE THE DEVELOPMENT AND IMPLEMENTATION OF A MANAGEMENT PLAN AND, IF NECESSARY, A RETROSPECTIVE REVIEW AND MITIGATION REPORT. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 2,185,602. MANAGEMENT AND GENERAL EXPENSES 61,000. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,246,602. FORM 990, PART XII, LINE 2C: THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. NRG ONCOLOGY FOUNDATION INC 1600 JFK BOULEVARD SUITE 1020 PHILADELPHIA PA 19103 900912747 ONCOLOGY RESEARCH SUPPORT PA 501(C)(3) LINE 7 N/A 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 NRG ONCOLOGY FOUNDATION INC C 3826038 ACTUAL GRANTS